Literature DB >> 14517580

Beclomethasone-induced vasoconstriction in women with major depressive disorder.

Nick J Coupland1, Kathleen M Hegadoren, Jessica Myrholm.   

Abstract

OBJECTIVE: It has been hypothesized that abnormal negative feedback of cortisol release in major depressive disorder (MDD) may involve impaired central glucocorticoid receptor (GR) function. Beclomethasone-induced vasoconstriction (BIV) was recently used to test the hypothesis that impaired GR function generalizes to peripheral tissues, and it was reported that BIV was decreased in medicated patients with MDD. The objective was to test the hypothesis that BIV would be reduced in unmedicated women with MDD compared with healthy controls.
DESIGN: Case-control.
SETTING: A university womens' mental health research unit. PARTICIPANTS: Women aged 18-65 years (n=19) diagnosed, according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, with MDD after a structured interview and clinical assessment. Healthy women pair-matched for age, reproductive and smoking status. PROCEDURES: BIV was tested using a range of beclomethasone dipropionate concentrations (1-100 microg/mL) applied to the forearm, with vasoconstriction scored visually after 15-18 hours by raters blinded to diagnosis and the randomization of the application sites. OUTCOME MEASURE: Visual scores for BIV at each beclomethasone concentration.
RESULTS: No significant differences between patients with MDD and controls were found. Postmenopausal women showed less of a response than premenopausal women or women taking sex-hormone preparations.
CONCLUSION: The study did not concur with the previous finding that BIV is decreased in MDD. Further research is needed to determine whether the difference in findings is due to medication or to other factors that may have distinguished the samples, including sex, age, reproductive status, illness severity, treatment resistance and setting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517580      PMCID: PMC193983     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  29 in total

Review 1.  Corticosteroids and vascular tone: mapping the messenger maze.

Authors:  B R Walker; B C Williams
Journal:  Clin Sci (Lond)       Date:  1992-06       Impact factor: 6.124

2.  Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure.

Authors:  G C Watt; S B Harrap; C J Foy; D W Holton; H V Edwards; H R Davidson; J M Connor; A F Lever; R Fraser
Journal:  J Hypertens       Date:  1992-05       Impact factor: 4.844

3.  Cutaneous vasoconstrictor response to glucocorticoids in asthma.

Authors:  P H Brown; S Teelucksingh; S P Matusiewicz; A P Greening; G K Crompton; C R Edwards
Journal:  Lancet       Date:  1991-03-09       Impact factor: 79.321

Review 4.  Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?

Authors:  A F Schatzberg; A J Rothschild
Journal:  Am J Psychiatry       Date:  1992-06       Impact factor: 18.112

5.  A comparison of techniques to assess skin blanching following the topical application of glucocorticoids.

Authors:  J P Noon; C E Evans; W G Haynes; D J Webb; B R Walker
Journal:  Br J Dermatol       Date:  1996-05       Impact factor: 9.302

6.  Correlation of the vasoconstrictor assay and clinical activity in psoriasis.

Authors:  R Woodford
Journal:  Arch Dermatol       Date:  1986-12

7.  A global measure of perceived stress.

Authors:  S Cohen; T Kamarck; R Mermelstein
Journal:  J Health Soc Behav       Date:  1983-12

8.  Neuroendocrine and other studies of the mechanism of antidepressant action of desipramine.

Authors:  S A Checkley; T H Corn; I B Glass; C Thompson; C Franey; J Arendt
Journal:  Ciba Found Symp       Date:  1986

9.  RU 486 inhibits peripheral effects of glucocorticoids in humans.

Authors:  R C Gaillard; D Poffet; A M Riondel; J H Saurat
Journal:  J Clin Endocrinol Metab       Date:  1985-12       Impact factor: 5.958

10.  Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension.

Authors:  B R Walker; R Best; C H Shackleton; P L Padfield; C R Edwards
Journal:  Hypertension       Date:  1996-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.